Quad, an investigational four-drug cocktail by Gilead Sciences, achieved a 90% response rate among HIV patients
in a Phase III trial, compared with 87% for those given Atripla, an approved treatment combining Gilead's two-in-one pill Truvada and Bristol-Myers Squibb's Sustiva. Gilead aims to file by year-end for FDA approval of Quad, said chief scientific officer Norbert Bischofberger.

Full Story:

Related Summaries